Botanix Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Botanix Pharmaceuticals CEO'su Howie McKibbon, Aug2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı A$ 3.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.3% maaş ve 84.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.22% ine doğrudan sahiptir ve bu hisseler A$ 1.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 5.3 yıldır.

Anahtar bilgiler

Howie McKibbon

İcra Kurulu Başkanı

AU$3.9m

Toplam tazminat

CEO maaş yüzdesi	15.3%
CEO görev süresi	1.3yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

CEO Tazminat Analizi

Howie McKibbon'un ücretlendirmesi Botanix Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$4m	AU$602k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$10m
Sep 30 2023	n/a	n/a	-AU$10m
Jun 30 2023	AU$1m	AU$542k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$585k	AU$126k	-AU$13m

Tazminat ve Piyasa: Howie 'nin toplam tazminatı ($USD 2.55M ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 910.64K ).

Tazminat ve Kazançlar: Howie şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Howie McKibbon

1.3yrs

Görev süresi

AU$3,923,813

Tazminat

Dr. Howie McKibbon serves as Chief Executive Officer since August 24, 2023 and was its Chief Operating Officer since October 2022 until August 24, 2023. He served as Chief Commercial Officer at Botanix Pha...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.5m
Howie McKibbon	Chief Executive Officer	1.3yrs	AU$3.92m	0.22% A$ 1.3m
Graeme Morissey	Chief Financial Officer	less than a year	AU$186.22k	Veri yok
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 23.9m
Jack Hoblitzell	Senior Vice President of Pharmaceutical Development	3.8yrs	Veri yok	Veri yok
Patricia Walker	Chief Medical Adviser	2.8yrs	Veri yok	Veri yok
Boris Meyerson	Chief Business Officer	less than a year	Veri yok	Veri yok
David Morgan	Head of Corporate Affairs	less than a year	Veri yok	Veri yok
Kevin Wojciechowski	Head of HCP Marketing & Sales Training	less than a year	Veri yok	Veri yok
Susan Park	Company Secretary	1.6yrs	Veri yok	Veri yok
Darin Van Arsdale	Director of Sales Operations	less than a year	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: BOT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.5m
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 23.9m
Stewart Washer	Independent Non-Executive Director	5.8yrs	AU$61.57k	0.12% A$ 694.4k
Henry Bosch	Non Executive Director	8.3yrs	AU$227.16k	1.04% A$ 6.0m
Daniel Sharp	Non-Executive Director	2.7yrs	AU$88.49k	0.12% A$ 682.0k

5.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BOT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Botanix Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş